secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001437749-23-008625
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports Q4 2022 net loss of $9.2M, no revenue; shifts focus to atrial fibrillation
--------------------------------------------------------------------------------

- Q4 2022 GAAP net loss of $9.2M vs $15.4M in Q4 2021; non-GAAP net loss $8.1M.
- No revenue in Q4 2022; full-year 2022 revenue $0.7M from discontinued dermatology.
- Cash, cash equivalents and investments $61.1M at Dec 31, 2022; cash burn reduced to $8.0M in Q4.
- Company focuses on nsPFA cardiac ablation for atrial fibrillation; FDA pre-submission for clamp planned in Q2 2023.
- Appointed Manmeet S. Soni as Lead Independent Director with $80,000 annual fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/0001437749-23-008625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/plse20230329_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer